Filtered By:
Vaccination: Meningitis Vaccine
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 2891 results found since Jan 2013.
Dynamics of invasive pneumococcal disease in infants & lt; 2 years old following PCV7/13 implementation using two infant and a booster dose schedule: evidence for indirect protection of young infants, Israel, 2004 to 2019
ConclusionsIndirect (herd) protection of infants, including < 4 month-olds with ≤ 1 PCV dose, was achieved by the 2+1 PCV schedule programme which thus seems adequate.PMID:37347413 | PMC:PMC10288828 | DOI:10.2807/1560-7917.ES.2023.28.25.2200765
Source: Euro Surveill - June 22, 2023 Category: Infectious Diseases Authors: Shalom Ben-Shimol Bart Adriaan van der Beek Meirav Mor Orli Megged Ron Dagan Israeli Pediatric Bacteremia and Meningitis Group (IPBMG) and the Microbiology Group Source Type: research
Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink
CONCLUSION: Combined pre-specified health outcomes observed among persons who received SV with COVID-19 vaccine were rare and not statistically significantly different compared to persons who did not receive SV with COVID-19 vaccine. Statistically significant adjusted rate ratios were observed for some individual outcomes, but the number of outcomes was small and there was no adjustment for multiple testing.PMID:37344264 | DOI:10.1016/j.vaccine.2023.06.042
Source: Vaccine - June 21, 2023 Category: Allergy & Immunology Authors: Tat'Yana A Kenigsberg Kayla E Hanson Nicola P Klein Ousseny Zerbo Kristin Goddard Stanley Xu W Katherine Yih Stephanie A Irving Laura P Hurley Jason M Glanz Robyn Kaiser Lisa A Jackson Eric S Weintraub Source Type: research
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A phase III study (V114-033)
CONCLUSION: In Japanese infants, a four-dose series of V114 was generally well tolerated. Compared with PCV13, V114 provided non-inferior immune responses to the 13 shared serotypes and higher immune responses to serotype 22F and 33F post-primary series.TRIAL REGISTRATION: ClinicalTrials.gov: NCT04384107; EudraCT 2019-003644-68.PMID:37344262 | DOI:10.1016/j.vaccine.2023.05.064
Source: Vaccine - June 21, 2023 Category: Allergy & Immunology Authors: Hiroko Suzuki Hidetoshi Fujita Kazuyuki Iwai Haruo Kuroki Kazuhiko Taniyama Toshiyuki Shizuya Hiroyuki Kishino Rie Igarashi Masayoshi Shirakawa Miyuki Sawata Source Type: research
Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink
CONCLUSION: Combined pre-specified health outcomes observed among persons who received SV with COVID-19 vaccine were rare and not statistically significantly different compared to persons who did not receive SV with COVID-19 vaccine. Statistically significant adjusted rate ratios were observed for some individual outcomes, but the number of outcomes was small and there was no adjustment for multiple testing.PMID:37344264 | DOI:10.1016/j.vaccine.2023.06.042
Source: Vaccine - June 21, 2023 Category: Allergy & Immunology Authors: Tat'Yana A Kenigsberg Kayla E Hanson Nicola P Klein Ousseny Zerbo Kristin Goddard Stanley Xu W Katherine Yih Stephanie A Irving Laura P Hurley Jason M Glanz Robyn Kaiser Lisa A Jackson Eric S Weintraub Source Type: research
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A phase III study (V114-033)
CONCLUSION: In Japanese infants, a four-dose series of V114 was generally well tolerated. Compared with PCV13, V114 provided non-inferior immune responses to the 13 shared serotypes and higher immune responses to serotype 22F and 33F post-primary series.TRIAL REGISTRATION: ClinicalTrials.gov: NCT04384107; EudraCT 2019-003644-68.PMID:37344262 | DOI:10.1016/j.vaccine.2023.05.064
Source: Vaccine - June 21, 2023 Category: Allergy & Immunology Authors: Hiroko Suzuki Hidetoshi Fujita Kazuyuki Iwai Haruo Kuroki Kazuhiko Taniyama Toshiyuki Shizuya Hiroyuki Kishino Rie Igarashi Masayoshi Shirakawa Miyuki Sawata Source Type: research
Adherence to vaccination guidelines of patients with complete splenectomy in Norway, 2008-2020
This study assessed vaccination coverage (VC) among Norwegian patients with surgical asplenia. Using the Nomesco Classification of Surgical Procedures codes, patient information (age, sex, date of initial diagnosis and date of surgery) was acquired from the Norwegian Patient Registry. The National Immunization Register provided information on vaccination status and data of any subsequent invasive bacterial infections were obtained from the Norwegian Surveillance System for Communicable Diseases. From the total population of Norway, 3155 patients who had undergone complete splenectomy were identified. Of these, 914 (29.0%) ...
Source: Vaccine - June 19, 2023 Category: Allergy & Immunology Authors: Saima Orangzeb Sara Viksmoen Watle Dominique A Caugant Source Type: research
Incidence and clinical outcomes of pneumonia in persons with down syndrome in the United States
CONCLUSIONS: Among persons with DS, incidence of pneumonia and associated hospitalizations were increased; mortality among those with pneumonia was comparable at 30 days, but higher at 1 year. DS should be considered an independent risk condition for pneumonia.PMID:37328350 | DOI:10.1016/j.vaccine.2023.05.063
Source: Vaccine - June 16, 2023 Category: Allergy & Immunology Authors: Edward N Janoff Hung-Fu Tseng Jennifer L Nguyen Tamuno Alfred Jeffrey Vietri Angee McDaniel Erica Chilson Qi Yan Deepa Malhotra Raul E Isturiz Myron J Levin Source Type: research
Epidemiology of invasive meningococcal disease in Canada, 2012-2019
CONCLUSION: Invasive meningococcal disease is a rare but severe infection in Canada that mostly affects the very young. Serogroup B continues to account for the greatest proportion of disease. Serogroup W associated with ST-11 CC is becoming a growing contributor of disease in all age groups not protected by serogroup W-containing vaccines.PMID:37325257 | PMC:PMC10263176 | DOI:10.14745/ccdr.v48i05a06
Source: Can Commun Dis Rep - June 16, 2023 Category: Infectious Diseases Authors: Myriam Saboui Raymond Sw Tsang Robert MacTavish Amisha Agarwal Y Anita Li Marina I Salvadori Susan G Squires Source Type: research
Incidence and clinical outcomes of pneumonia in persons with down syndrome in the United States
CONCLUSIONS: Among persons with DS, incidence of pneumonia and associated hospitalizations were increased; mortality among those with pneumonia was comparable at 30 days, but higher at 1 year. DS should be considered an independent risk condition for pneumonia.PMID:37328350 | DOI:10.1016/j.vaccine.2023.05.063
Source: Vaccine - June 16, 2023 Category: Allergy & Immunology Authors: Edward N Janoff Hung-Fu Tseng Jennifer L Nguyen Tamuno Alfred Jeffrey Vietri Angee McDaniel Erica Chilson Qi Yan Deepa Malhotra Raul E Isturiz Myron J Levin Source Type: research
Epidemiology of invasive meningococcal disease in Canada, 2012-2019
CONCLUSION: Invasive meningococcal disease is a rare but severe infection in Canada that mostly affects the very young. Serogroup B continues to account for the greatest proportion of disease. Serogroup W associated with ST-11 CC is becoming a growing contributor of disease in all age groups not protected by serogroup W-containing vaccines.PMID:37325257 | PMC:PMC10263176 | DOI:10.14745/ccdr.v48i05a06
Source: Can Commun Dis Rep - June 16, 2023 Category: Infectious Diseases Authors: Myriam Saboui Raymond Sw Tsang Robert MacTavish Amisha Agarwal Y Anita Li Marina I Salvadori Susan G Squires Source Type: research
Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: A systematic review
CONCLUSION: Both vaccine outcomes showed real-life effectiveness of 4CMenB vaccine despite differences in study methodologies and vaccination strategies. Based on appraisal of study methods, we highlighted the need for an adapted tool which facilitates synthesis of heterogenic real-world vaccine studies when quantitative pooling methods are not applicable.PMID:37321895 | DOI:10.1016/j.vaccine.2023.05.025
Source: Vaccine - June 15, 2023 Category: Allergy & Immunology Authors: Elisa Cinconze Dominique Rosillon Rino Rappuoli Kumaran Vadivelu Rafik Bekkat-Berkani Victoria Abbing-Karahagopian Source Type: research
